α6GABAA receptor positive allosteric modulators targeting trigeminal ganglia for preventing and aborting chronic periorbital allodynia and cephalic pain in both sexes: A mechanistic and comparative preclinical study

Xin Chen Chang, Chen Jiun Yeh, Yi Ting Pan, Yueh Peng Chen, Dishary Sharmin, James Cook, Yu Cheng Pei, Lih Chu Chiou*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

Migraine remains an unmet medical need, even with new calcitonin gene-related peptide (CGRP)-targeting treatments. The α6 subunit (Gabra6)-containing GABAA receptors (α6GABAARs) are abundant in trigeminal ganglia (TG). We evaluated the possible anti-migraine efficacy and mechanism of DK-I-56–1, a druggable α6GABAAR-selective positive allosteric modulator (PAM), using a chronic migraine model induced by repeated intermittent nitroglycerin (riNTG) injections (10 mg/kg, i.p., every 2 days for a total of 5 doses). Chronic and acute allodynic responses of riNTG-treated ICR mice of both sexes were assessed by reduced mechanical withdrawal thresholds in their periorbital areas, and their chronic cephalic pain by elevated grimace scores. riNTG induced long-lasting chronic periorbital allodynia and cephalic pain, and one NTG injection caused acute allodynia. Daily DK-I-56–1 prevented chronic allodynia and cephalic pain, and abolished acute allodynia in both sexes. Anti-allodynic and cephalic pain-relieving effects of DK-I-56–1 (10 mg/kg, i.p.) were mimicked by topiramate (30 mg/kg, i.p.), antagonized by i.p. furosemide, an α6GABAAR antagonist, and nullified in Gabra6-knockout ICR mice. However, olcegepant (1 mg/kg, i.p.) only partially prevented cephalic pain. In dissociated TG neurons, DK-I-56–1 induced a furosemide-sensitive potentiation of GABA-induced current and depolarization. However, DK-I-56–1 did not altered increased inflammatory cytokines, down-regulated glutamate decarboxylase 65 kDa (GAD65), and Gabra6 protein levels in TG of riNTG-treated mice. Therefore, DK-I-56–1 may have the potential to prevent and abort migraines by potentiating GABA-induced depolarization in TG neurons via α6GABAARs, offering efficacy comparable to that of topiramate but superior to olcegepant as a novel migraine therapy.

Original languageEnglish
Article number118344
Pages (from-to)118344
JournalBiomedicine and Pharmacotherapy
Volume189
DOIs
StatePublished - 08 2025

Bibliographical note

Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Keywords

  • CGRP
  • GABA receptor
  • Migraine
  • Mouse grimace scale
  • Nitroglycerin
  • Periorbital allodynia
  • Trigeminal ganglia
  • Allosteric Regulation/drug effects
  • Hyperalgesia/prevention & control
  • Trigeminal Ganglion/drug effects
  • Male
  • Mice, Inbred ICR
  • Animals
  • Female
  • Mice
  • Receptors, GABA-A/metabolism
  • Migraine Disorders/drug therapy
  • Disease Models, Animal

Fingerprint

Dive into the research topics of 'α6GABAA receptor positive allosteric modulators targeting trigeminal ganglia for preventing and aborting chronic periorbital allodynia and cephalic pain in both sexes: A mechanistic and comparative preclinical study'. Together they form a unique fingerprint.

Cite this